I sure feel the same as you Kelsee. I’ve been reading and highlighting points in the press release and points made by BDAZ and I don’t have time to properly assemble them with proper attribution but here are a couple. I’m really excited about what this might do for the potential of zen3694 but of course it is a sample of N=1 so at this stage I’m hopeful but cautious. At least it is proven on a sample of N=1. As bear points out, perhaps this research may be extended to the other 2 super stars or more in the combo trial.

Also it is so nice to finally get some news on Zenith and so nice that in this case the hypothesis of the design of zen3694 is supported and now we have evidence that the impact can be improved and perhaps at some point optimized.  

Note that the underlining and quotes are my doing.

1) Bdaz - Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

in response to 

Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

 by 

BearDownAZ

posted on Sep 02, 2018 12:27PM

·       (near the end of Bear’s post) I wonder if all patients in the Phase 2 portion of the enzalutamide/ZEN-3694 combo mCRPC trial will have CURATE.AI informed dosing?

·       Very exciting that Zenith's ZEN-3694 was chosen as the proof-of-principle example (of CURATE.AI) to use in this publication!

My thought – The fact that this trial was chosen and demonstrated some form of success for zen3694 should give this unknown company “Zenith Epi” a boost in visibility, credibility and relevance at least in the scientific community but also because of the high profile of “anything AI” the interest should spread to the investment communities. Also, it seems to demonstrate that there is something bubbling out there in the science community about Zenith I think.

31 August 2018 | Research

·       Professor Dean Ho (left) and Mr Theodore Kee (right) from the National University of Singapore, together with their translational research team, harnessed CURATE.AI to successfully treat a patient with advanced cancer, completely halting disease progression.

·       The research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a “completely normal and active lifestyle”.

·       The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimised personalised medicine,” explained Professor Dean Ho, Director of the Singapore Institute for Neurotechnology (SINAPSE) at NUS, who led the study.  

·       “No two patients’ profiles are alike, and as a patient’s body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an “unprecedented” advance for combination therapy,” Prof Ho explained. 

·       Initially, the doses of ZEN-3694 and enzalutamide were adjusted by the clinicians to better manage patient-reported quality of life.

·       As treatment progressed, slight increases in ZEN-3694 dosing resulted in clear decreases in PSA levels, also demonstrating its key role in suppressing the metastatic cancer.

·       CT imaging of the patient’s lesions showed that disease progression was “halted” as a result of CURATE.AI-guided combination therapy of both ZEN-3694 and enzalutamide. Patient care guided by CURATE.AI is currently ongoing.

·       “Using CURATE.AI to dynamically modify drug doses and successfully treat a metastatic cancer patient represents a landmark breakthrough for the use of AI to truly personalise patient care.

·       Dr Allan Pantuck, …“The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.

-------------------

Great news and hopefully we'll hear more pre Sept 12th.

Glta

Toinv

S